ABBV vs NVDA: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and NVIDIA Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-26.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
NVIDIA Corporation · Technology
$225.07
+45.0% upside to fair value
Med Conviction
Grade B
High Quality
QuantHub Verdict
NVDA has more upside to fair value
(+45.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
NVDA |
| Current Price |
$261.70 |
$225.07 |
| Fair Value Estimate |
$259.04 |
$326.35 |
| Upside to Fair Value |
-1.0%
|
+45.0%
|
| Market Cap |
$462.4B |
$5,451.4B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
23.4x
|
| Price / Sales |
7.2x
|
18.0x
|
| Price / FCF |
23.6x
|
42.9x
|
| Revenue Growth YoY |
+10.2%
|
+105.9%
|
| Gross Margin |
71.5%
|
74.7%
|
| Operating Margin |
29.3%
|
65.2%
|
| Return on Equity |
-136.5%
|
110.1%
|
| Dividend Yield |
2.61% |
0.23% |
| FCF Yield |
4.25%
|
2.33%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
NVIDIA designs the accelerated computing platforms at the center of the AI buildout, spanning data center GPUs, Mellanox networking, AI enterprise software, gaming GeForce GPUs, professional visualization, and automotive platforms, with 42,000 employees and a $5.45 trillion market capitalization. Business quality is exceptional on the fundamentals: TTM gross margin of 74.7%, TTM operating margin …
Accumulation Zones
| Metric |
ABBV |
NVDA |
| Zone Low |
$194.28 |
$244.76 |
| Zone High |
$220.18 |
$277.40 |
| In Buy Zone? |
No
|
Yes
|